Zipalertinib Shows Early Efficacy With Manageable Safety in EGFR-Mutant NSCLC With CNS or Leptomeningeal Disease

Zipalertinib Shows Early Efficacy With Manageable Safety in EGFR-Mutant NSCLC With CNS or Leptomeningeal Disease

The intracranial objective response rate (ORR) in RANO-BM–evaluable patients (n = 16) was 31.3% (n = 5), which included 1 intracranial complete response. Notably, 2 of 5 intracranial responders also had leptomeningeal disease at baseline, and…

Continue Reading